Evidence map›Paper›PMID 36781679›Full record

ArticleInternational urology and nephrology2023

Real-world outcomes of patients with renal cell carcinoma, surgically treated at regional hospitals, based on a prospective long-term survey of the pre-robotic era.

Yoshihide Kawasaki, Hideo Saito, Naomasa Ioritani, Tatsuo Tochigi, Isamu Numata, Kenji Numahata, Fumihiko Soma, Atsushi Kyan, Shigeto Ishidoya, Shozo Ota and 6 more

Open access · hybridFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in International urology and nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Yoshihide KawasakiTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan. kawasaki@uro.med.tohoku.ac.jp.ORCID http://orcid.org/0000-0001-6425-3574
Hideo SaitoTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
Naomasa IoritaniTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
Tatsuo TochigiTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
Isamu NumataTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
Kenji NumahataTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
Fumihiko SomaTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
Atsushi KyanTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
Shigeto IshidoyaTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
Shozo OtaTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
Takashige NamimaTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
Kazuhiko OrikasaTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
Shinichi YamashitaTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
Koji MitsuzukaTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
Yoichi AraiTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
Akihiro ItoTohoku Urological Evidence-Based Medicine Study Group, Japan (Japan Community Health Care Organization Sendai Hospital, Miyagi Cancer Center, Osaki Citizen Hospital, Yamagata Prefectural Central Hospital, Hachinohe City Hospital, Shirakawa Kosei General Hospital, Sendai City Hospital, Sendai Red Cross Hospital, Tohoku Rosai Hospital, Kesennuma City Hospital, Sen-en Rifu Hospital, Iwate Prefectural Iwai Hospital, KKR Tohoku Kosai Hospital, and Tohoku University Hospital), Sendai, Japan.
KKR Tohoku Kosai Hospital · JPTohoku University · JP

Funding

Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology 20K07582Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology K426462393
6 · The paper itself

Abstract

purposeRenal cancer surgery is frequently performed in small regional hospitals in Japan. This study evaluated the outcomes of renal cancer surgery, comparing results from the pre-robotic surgery era with those obtained with robotic surgery.

methodsThis prospective cohort study was conducted on patients who underwent renal cancer surgery between 2008 and 2013 at 14 hospitals, comprising 13 regional hospitals and a university hospital, registered in the Tohoku Urological Evidence-Based Medicine Study Group. The patients' backgrounds; perioperative data; annual postoperative renal function; and prognostic surveys, performed over a median follow-up period of 10 years were obtained.

resultsIn 930 surgical cases at the 14 registered hospitals, the 10-year recurrence-free survival rates of cT1a, cT1b, cT2, and cT3 were 0.9326, 0.8501, 0.5786, and 0.5101, respectively. Meanwhile, the 10-year overall survival rates were 0.9612, 0.8662, 0.7505, and 0.7209, respectively. Long-term observation in patients with cT1 showed that vessel involvement and high tumor grade were prognostic factors for recurrence. As a noteworthy fact, radical nephrectomy was performed in 53.3% of patients with cT1a at the regional hospitals. However, even in patients with preoperative chronic kidney disease stage 3, radical nephrectomy was not a prognostic factor of renal function. This indicates that compensatory mechanisms had been working for a long time in many patients who underwent radical nephrectomies without hypertension and preoperative proteinuria, which were predictors of end-stage renal disease.

conclusionBased on a prospective long-term survey of the pre-robotic era, our results suggested no difference of the survival outcomes between the university hospital and regional hospitals. Our study provides baseline data to evaluate the outcomes of renal cancer robotic surgery, performed at regional hospitals.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsRobotic Surgical ProceduresHospitals, UniversityHumansProspective StudiesRetrospective StudiesClinical T1Prospective cohortRadical nephrectomyRegional hospitalRenal cancerRenal function

Identifiers

PMID36781679
PMCPMC10030418
OpenAlexW4320709499

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read13
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.